IGF1R and head and neck squamous cell carcinoma: Other RTKs that are currently investigated in clinical trials for patients with HNSCC include the insulin-like growth factor 1 receptor (IGF1R) [16] and the MET proto-oncogene receptor tyrosine kinase (MET) in combination with the vascular endothelial growth factor receptor (VEGFR) [17].